Paul M. Silva

CIK: 0001446372

Transaction Breakdown

Open Market Buys (P)1 (16.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (83.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

RAPP

Rapport Therapeutics, Inc.

Director

NRIX

Nurix Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

RAPP
Rapport Therapeutics, Inc.
Oct 22, 2026
Purchase(P)
Indirect
3.7K shares at avg. $27.07$100K
RAPP
Rapport Therapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Buy)
Direct
15.2K shares-
NRIX
Nurix Therapeutics, Inc.
May 15, 2026
Award(A)
Director Stock Option (right to buy)
Direct
31.3K shares-
RAPP
Rapport Therapeutics, Inc.
Jun 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
10.9K shares-
NRIX
Nurix Therapeutics, Inc.
May 19, 2025
Award(A)
Director Stock Option (right to buy)
Direct
25K shares-
RAPP
Rapport Therapeutics, Inc.
Nov 7, 2024
Award(A)
Stock Option (Right to Buy)
Direct
29.8K shares-

		Type	Shares	Price		Ownership
Oct 22, 2026	RAPP Rapport Therapeutics, Inc.	Purchase(P)	3,680	$27.07	$99,636	Indirect
Jun 10, 2026	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	15,200	-	-	Direct
May 15, 2026	NRIX Nurix Therapeutics, Inc.	Award(A) Director Stock Option (right to buy)	31,250	-	-	Direct
Jun 17, 2025	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	10,925	-	-	Direct
May 19, 2025	NRIX Nurix Therapeutics, Inc.	Award(A) Director Stock Option (right to buy)	25,000	-	-	Direct
Nov 7, 2024	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	29,756	-	-	Direct

1-6 of 6 transactions

About Silva Paul M

Silva Paul M (SEC CIK 0001446372) files insider reports with the SEC as Director of Rapport Therapeutics, Inc. (RAPP) and Director of Nurix Therapeutics, Inc. (NRIX).

Signal8 holds 7 ownership filings by Silva Paul M (1 Form 3, 6 Form 4), filed between Nov 7, 2024 and Oct 22, 2026. Those filings report 6 transactions, from Nov 7, 2024 to Oct 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Silva Paul M's filings is in BOSTON, MA.

Recent filings by Silva Paul M

Oct 22, 2026: Open-market purchase of RAPP shares (Form 4, code P).
Jun 10, 2026: Grant or award of RAPP derivative securities (Form 4, code A).
May 15, 2026: Grant or award of NRIX derivative securities (Form 4, code A).
Jun 17, 2025: Grant or award of RAPP derivative securities (Form 4, code A).
May 19, 2025: Grant or award of NRIX derivative securities (Form 4, code A).

Other insiders filing for Rapport Therapeutics, Inc. (RAPP)

HEALY JAMES, Director
Ceesay Abraham, Chief Executive Officer
Sanchez Ramiro, Director
Young Wendy B., Director
PAUL STEVEN M, Director
MARAGANORE JOHN, Director

How to read Form 4 transaction codes